Two Anti-Cancer Drugs Provide Benefits for Patients with Advanced Papillary Kidney Cancer

Among 20 patients with a form of papillary renal cell carcinoma (pRCC) called hereditary leiomyomatosis and renal cell cancer (HLRCC) who were treated with bevacizumab and erlotinib, the response rate was 65%, with 13 patients showing tumor shrinkage >30% and 7 patients with stable disease. Among 21 patients with sporadic pRCC who were treated with the combination, the response rate was 29%, with 6 patients showing tumor shrinkage and 12 patients with stable disease. HLRCC and pRCC patients survived without disease progression for a median of 24.2 and 7.4 months, respectively. The results were presented at an EORTC-NCI-AACR symposium.

Category:
Subcategory:
Body:

Among 20 patients with a form of papillary renal cell carcinoma (pRCC) called hereditary leiomyomatosis and renal cell cancer (HLRCC) who were treated with bevacizumab and erlotinib, the response rate was 65%, with 13 patients showing tumor shrinkage >30% and 7 patients with stable disease. Among 21 patients with sporadic pRCC who were treated with the combination, the response rate was 29%, with 6 patients showing tumor shrinkage and 12 patients with stable disease. HLRCC and pRCC patients survived without disease progression for a median of 24.2 and 7.4 months, respectively. The results were presented at an EORTC-NCI-AACR symposium.